Slate Run Pharmaceuticals 2026-03-04 Health moderate FDA
Health · FDA · Recall #FDA-D-0343-2026
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL… Recall
Issued March 4, 2026 · Slate Run Pharmaceuticals
In March 2026, Slate Run Pharmaceuticals recalled the Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL…, a moderate health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
What you should do
- 1 Stop using Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Slate Run Pharmaceuticals to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Slate Run Pharmaceuticals
- Category
- Health
- Recall date
- March 4, 2026
- Units affected
- Not reported
- Sold at
- Nationwide within the USA.
- Recall number
- FDA-D-0343-2026
- Made in
- United States
- Issuing agency
- FDA
In context
- Slate Run Pharmaceuticals has 2 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 356th Health recall we've logged in 2026.